Current evidence is insufficient to recommend GLP-1 receptor agonists as standard therapy for rheumatoid arthritis, requiring well-designed RCTs to establish efficacy.
Do GLP-1 receptor agonists improve outcomes in patients with rheumatoid arthritis?
There is currently insufficient evidence to recommend GLP-1 receptor agonists as standard therapy for rheumatoid arthritis, highlighting the need for dedicated randomized controlled trials.
Absolute Event Rate: 0% vs 0%
Present evidence is insufficient to recommend GLP-1 RAs as standard RA therapy. Well designed randomized controlled trials are needed to establish their efficacy and optimal role.
Massay et al. (Wed,) reported a other. Current evidence is insufficient to recommend GLP-1 receptor agonists as standard therapy for rheumatoid arthritis, requiring well-designed RCTs to establish efficacy.